A generic version of Takeda Pharmaceuticals’ proton pump inhibitor Prevacid DR Capsules, this most recent approval comes after their tentative FDA approval for the company's fixed-dose combination of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate tablets for the treatment of HIV.
Right now, Mylan has 125 ANDAs pending FDA approval representing annual brand sales of $84.1 billion.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
